In addition, the majority of chemotherapy regimens for breast cancer patients with positive HR and HER-2 contained platinum, such as 6-period Docetaxel combined with carboplatin and Trastuzumab (6TCbH) regimen in our research. Here, ERBB2 is linked to breast carcinoma.